English   español  

Browsing by Author Richardson, Paul G.

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
or enter first few letters:  
Showing results 1 to 14 of 14
RightsPreviewIssue DateTitleAuthor(s)Type
closedAccessaccesoRestringido.pdf.jpg2017A retrospective analysis of 3954 patients in phase 2/3 trials of bortezomib for the treatment of multiple myeloma: towards providing a benchmark for the cardiac safety profile of proteasome inhibition in multiple myelomaLaubach, Jacob P.; Moslehi, Javid J.; Francis, Sanjeev A.; San Miguel, Jesús F. CSIC ORCID; Sonneveld, Pieter; Orlowski, R. Z.; Moreau, Philippe; Rosiñol, Laura; Faber Jr., Edward A.; Voorhees, Peter; Mateos, Maria Victoria; Marquez, Loreta; Feng, Huaibao; Desai, Avinash; Velde, Helgi van de; Elliott, Jennifer; Shi, Hongliang; Dow, Edward; Jobanputra, Nishith; Esseltine, Dixie-Lee; Niculescu, Liviu; Anderson, Kenneth; Lonial, Sagar; Richardson, Paul G.artículo
openAccessAssociation_Garderet_PV_Art2018.pdf.jpg2018Association between response kinetics and outcomes in relapsed/refractory multiple myeloma: analysis from TOURMALINE-MM1Garderet, Laurent; Laubach, Jacob P.; Stoppa, Anne-Marie; Hari, Parameswaran; Cavo, Michele; Ludwig, Heinz; Mateos, Maria Victoria; Luptakova, Katarina; Lin, Jianchang; Yung, Godwin; Velde, Helgi van de; Berg, Deborah; Moreau, Philippe; Richardson, Paul G.artículo
closedAccessaccesoRestringido.pdf.jpg2014Bortezomib cumulative dose, efficacy, and tolerability with three different bortezomib-melphalan-prednisone regimens in previously untreated myeloma patients ineligible for high-dose therapyMateos, Maria Victoria; Bringhen, Sara; Richardson, Paul G.; Lahuerta, Juan José; García-Sanz, Ramón; San Miguel, Jesús F. CSIC ORCID; Palumbo, Antonioartículo
closedAccessaccesoRestringido.pdf.jpg2011Characterization of haematological parameters with bortezomib-melphalan-prednisone versus melphalan-prednisone in newly diagnosed myeloma, with evaluation of long-term outcomes and risk of thromboembolic events with use of erythropoiesis-stimulating agents: Analysis of the VISTA trialRichardson, Paul G.; Mateos, Maria Victoria; San Miguel, Jesús F. CSIC ORCIDartículo
closedAccessaccesoRestringido.pdf.jpg2016Clinical efficacy and management of monoclonal antibodies targeting CD38 and SLAMF7 in multiple myelomaDonk, Niels W. C. J. van de; Moreau, Philippe; Plesner, Torben; Palumbo, Antonio; Gay, Francesca; Laubach, Jacob P.; Malavasi, Fabio; Avet-Loiseau, Hervé; Mateos, Maria Victoria; Sonneveld, Pieter; Lokhorst, Henk M.; Richardson, Paul G.artículo
closedAccessaccesoRestringido.pdf.jpg2011Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1Rajkumar, S. Vincent; Richardson, Paul G.; Lonial, Sagar; San Miguel, Jesús F. CSIC ORCIDartículo
closedAccessaccesoRestringido.pdf.jpg2011Future Directions of Next-Generation Novel Therapies, Combination Approaches, and the Development of Personalized Medicine in MyelomaMitsiades, C. S.; San Miguel, Jesús F. CSIC ORCID; Richardson, Paul G.artículo
closedAccessaccesoRestringido.pdf.jpg2012Management of treatment-emergent peripheral neuropathy in multiple myelomaRichardson, Paul G.; Lahuerta, Juan José; Mateos, Maria Victoria; Bladé, Joan; San Miguel, Jesús F. CSIC ORCIDartículo
openAccessnihms-manuscript.pdf.jpg2016Myeloma cell dynamics in response to Treatment supports a model of hierarchical differentiation and clonal evolutionTang, Min; Zhao, Rui; Velde, Helgi van de; Tross, Jennifer G.; Mitsiades, C. S.; Viselli, Suzanne; Neuwirth, Rachel; Esseltine, Dixie-Lee; Anderson, Kenneth; Ghobrial, Irene M.; San Miguel, Jesús F. CSIC ORCID; Richardson, Paul G.; Tomasson, Michael H.; Michor, Franziskaartículo
closedAccessaccesoRestringido.pdf.jpg2014New drugs and novel mechanisms of action in multiple myeloma in 2013: a report from the International Myeloma Working Group (IMWG)Ocio, Enrique M. CSIC ORCID ; Richardson, Paul G.; Rajkumar, S. Vincent; Palumbo, Antonio; Mateos, Maria Victoria; Orlowski, R. Z.; Kumar, S.; Dimopoulos, Meletios A.; Merlini, Giampolo; Lahuerta, Juan José; Lonial, Sagar; Moreau, Philippe; Ludwig, Heinz; San Miguel, Jesús F. CSIC ORCIDartículo
openAccesspersistentoverall.pdf.jpg2013Persistent overall survival benefit and no increased risk of second malignancies with bortezomib-melphalan-prednisone versus melphalan-prednisone in patients with previously untreated multiple myelomaSan Miguel, Jesús F. CSIC ORCID; Dimopoulos, Meletios A.; Palumbo, Antonio; Delforge, Michel; Mateos, Maria Victoria; Richardson, Paul G.artículo
closedAccessaccesoRestringido.pdf.jpg2012Proteasome inhibitors in multiple myeloma: 10 years laterMoreau, Philippe; Richardson, Paul G.; Cavo, Michele; Orlowski, R. Z.; San Miguel, Jesús F. CSIC ORCID; Palumbo, Antonio; Harousseau, Jean-Lucartículo
closedAccessaccesoRestringido.pdf.jpg2009Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guidelineRichardson, Paul G.; San Miguel, Jesús F. CSIC ORCIDartículo
closedAccessaccesoRestringido.pdf.jpg2011Risk factors for, and reversibility of, peripheral neuropathy associated with bortezomib–melphalan–prednisone in newly diagnosed patients with multiple myeloma: subanalysis of the phase 3 VISTA studyDimopoulos, Meletios A.; Mateos, Maria Victoria; Richardson, Paul G.; San Miguel, Jesús F. CSIC ORCIDartículo